Cost Curve
everything drug pricing and policy, every day
Connect
And pieces on how to make our system more value-driven, the fate of PBM reform, and what Oz may do with IRA
And ICER says that Vertex's non-opioid pain med looks like a fantastic deal
Plus an important update on how to think about the pharmacy-closure story from last week
And another set of guesses on which drugs will be next up for price controls
And Michigan is set to be the next 340B battleground. Could the Wolverine State learn from the experience of the Gopher State?
And a breathless Reuters story suggests that industry thinks IRA fixes are in play during Trump 2.0
Plus links on gene therapy financing, BMS' 340B statement, and more importation skepticism
Otherwise: 🦃🦃🦃
Plus the Biden administration makes a move to cover obesity meds in Medicare and Medicaid ... but will it matter?
The data has some gaps -- as the state recognizes -- but it's still a fantastic resource for seeing how the program operates at a more granular level
And trying to catch up on everything from IP reform to 340B messaging
And the Oregon PDAB continues its shenanigans
